News
Adaptimmune Appoints Elliot Norry as Chief Medical Officer
www.globenewswire.com
Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science...
Close Biotechgate Biotechgate | | Twitter LinkedIn Google+ ...canadianlifesciences.com › gate
canadianlifesciences.com
... patients for the Phase 2 SPEARHEAD-1 trial,” said Elliot Norry, Adaptimmune's acting Chief Medical Officer. “We expect that all sites for SPEARHEAD-1 will be ...
Regenerative Medicine Advanced Therapy Designation ...www.teletrader.com › news › details
www.teletrader.com
... our ADP-A2M4 therapy to market in for patients with synovial sarcoma,” said Elliot Norry, Adaptimmune's acting Chief Medical Officer.
T-cell therapy receives FDA's orphan drug status for soft tissue ...www.healio.com › news › online
www.healio.com
Elliot Norry. The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell ...
sortiert nach Relevanz / Datum